Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report.

Strobbe, Geoffrey; Pannier, Diane; Sakji, Ilyes; Villain, Alexandre; Feutry, Frédéric; Marliot, Guillaume

Strobbe, Geoffrey; Pannier, Diane; Sakji, Ilyes; Villain, Alexandre; Feutry, Frédéric; Marliot, Guillaume.

Afiliação

Strobbe G; Service of Pharmacy, Centre Oscar Lambret, Lille, France.
Pannier D; Medical Oncology Department, Centre Oscar Lambret, Lille, France.
Sakji I; Service of Pharmacy, Centre Oscar Lambret, Lille, France.
Villain A; Service of Pharmacy, Centre Oscar Lambret, Lille, France.
Feutry F; Service of Pharmacy, Centre Oscar Lambret, Lille, France.
Marliot G; Service of Pharmacy, Centre Oscar Lambret, Lille, France.

J Oncol Pharm Pract ; 26(7): 1743-1749, 2020 Oct.

Article em En | MEDLINE | ID: mdl-32070198

Assuntos

Monitoramento de Medicamentos; Everolimo/uso terapêutico; Verapamil/administração & dosagem; Carcinoma de Células Renais/tratamento farmacológico; Interações Medicamentosas; Feminino; Humanos; Imunossupressores/administração & dosagem; Neoplasias Renais/tratamento farmacológico; Pessoa de Meia-Idade

Palavras-chave

Therapeutic drug monitoring; drugdrug interaction; everolimus; renal cell carcinoma; verapamil

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Verapamil / Monitoramento de Medicamentos / Everolimo Tipo de estudo: Guideline Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google